Position in BCYC
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,276,000
-$671,000 QoQ
Shares Held
275,000
0.0% QoQ
Ownership
0.393%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BCYC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026MOORE CAPITAL MANAGEMENT, LP holds $51,235,346 across 22 Biotechnology names. BCYC ranks #17 (2.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IMCR |
Immunocore Holdings plc
|
197,308 | $5,948,836 | |
| 2 | GMAB |
Genmab A/S
|
211,705 | $5,680,045 | |
| 3 | RVMD |
Revolution Medicines, Inc.
|
55,600 | $5,407,100 | |
| 4 | IRON |
Disc Medicine, Inc.
|
57,796 | $3,695,476 | |
| 5 | ATAI |
AtaiBeckley Inc.
|
952,380 | $3,371,425 | |
| 6 | RARE |
Ultragenyx Pharmaceutical Inc.
|
157,132 | $3,291,915 | |
| 7 | PTCT |
Ptc Therapeutics, Inc.
|
44,694 | $3,045,002 | |
| 8 | REPL |
Replimune Group, Inc.
|
311,124 | $2,380,098 |
All Filings in BCYC
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,276,000 | 275,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,947,000 | 275,000 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $967,500 | 125,000 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $521,250 | 75,000 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $424,500 | 50,000 | Shares | Sole | 2025-08-12 | |
| No filing history on record for this holder in this stock. | ||||||